Cure My Disease

Don't miss your cure!

 Log in / Sign up

Multiple sclerosis CAR-T trial pulled before it even started

NCT ID NCT07364487

Terminated Disease control Sponsor: Huashan Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study aimed to test a single infusion of GC012F CAR-T cells in people with multiple sclerosis. The goal was to check safety and see if the treatment could control the disease. However, the trial was withdrawn before enrolling any participants, so no data was collected.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
GC012F CAR-T cell injection
What this could lead to
If it had worked, this could point toward a new way to control multiple sclerosis by targeting immune cells.
What could go wrong
This trial was withdrawn before any participants were enrolled, so no results are available. CAR-T therapies carry risks like severe immune reactions and infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE SCLEROSIS

Contacts and locations

Locations

  • Huashan Hospital Affiliated to Fudan University

    Shanghai, Shanghai Municipality, 200040, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.